Roivant Sciences Ltd. $ROIV Shares Bought by Invesco Ltd.

Key Points

• Invesco Ltd. increased its stake in Roivant Sciences Ltd. by 3.8%, owning 9,880,526 shares valued at approximately $99.7 million as of its latest SEC filing.
• Other hedge funds have also raised their positions, with TOMS Capital increasing holdings by 46.6% and Marshall Wace by 104.4% during the fourth quarter.
• Roivant Sciences had a negative net margin of 2,111.79% and reported earnings per share of ($0.31), missing analysts' estimates by ($0.15).

Invesco Ltd. boosted its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 3.8% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,880,526 shares of the company's stock after purchasing an additional 365,468 shares during the quarter. Invesco Ltd. owned approximately 1.38% of Roivant Sciences worth $99,695,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Patient Square Capital LP boosted its position in Roivant Sciences by 2.1% during the fourth quarter. Patient Square Capital LP now owns 12,480,000 shares of the company's stock worth $147,638,000 after purchasing an additional 251,535 shares in the last quarter. Two Seas Capital LP boosted its position in Roivant Sciences by 4.6% during the fourth quarter. Two Seas Capital LP now owns 10,167,807 shares of the company's stock worth $120,285,000 after purchasing an additional 442,914 shares in the last quarter. TOMS Capital Investment Management LP boosted its position in Roivant Sciences by 46.6% during the fourth quarter. TOMS Capital Investment Management LP now owns 5,885,000 shares of the company's stock worth $69,620,000 after purchasing an additional 1,870,000 shares in the last quarter. BlackBarn Capital Partners LP boosted its position in Roivant Sciences by 3.1% during the fourth quarter. BlackBarn Capital Partners LP now owns 4,125,000 shares of the company's stock worth $48,799,000 after purchasing an additional 125,000 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Roivant Sciences by 16.3% during the first quarter. Bank of New York Mellon Corp now owns 4,000,181 shares of the company's stock worth $40,362,000 after purchasing an additional 560,641 shares in the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Stock Down 0.4%

Shares of ROIV traded down $0.05 during mid-day trading on Tuesday, reaching $11.76. 3,452,711 shares of the stock traded hands, compared to its average volume of 5,805,721. The firm has a market cap of $7.99 billion, a price-to-earnings ratio of -16.80 and a beta of 1.15. The stock has a fifty day simple moving average of $11.39 and a 200 day simple moving average of $10.89. Roivant Sciences Ltd. has a 12-month low of $8.73 and a 12-month high of $13.06.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings data on Thursday, May 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.15). The firm had revenue of $7.57 million for the quarter, compared to analysts' expectations of $62.17 million. Roivant Sciences had a negative net margin of 2,111.79% and a negative return on equity of 15.90%. During the same quarter in the prior year, the business earned ($0.23) EPS. On average, equities research analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Eric Venker sold 100,000 shares of the firm's stock in a transaction dated Monday, July 21st. The stock was sold at an average price of $11.52, for a total transaction of $1,152,000.00. Following the completion of the sale, the chief executive officer directly owned 1,462,223 shares in the company, valued at $16,844,808.96. This trade represents a 6.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Vivek Ramaswamy sold 577,007 shares of Roivant Sciences stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $11.46, for a total value of $6,612,500.22. Following the completion of the transaction, the insider owned 37,284,108 shares of the company's stock, valued at approximately $427,275,877.68. The trade was a 1.52% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,090,503 shares of company stock valued at $34,991,546 over the last 90 days. Insiders own 10.80% of the company's stock.

Analysts Set New Price Targets

ROIV has been the subject of a number of analyst reports. The Goldman Sachs Group raised Roivant Sciences to a "strong-buy" rating and set a $19.00 price target for the company in a report on Thursday, July 10th. HC Wainwright reiterated a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a report on Wednesday, June 18th. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, Roivant Sciences currently has an average rating of "Buy" and an average target price of $16.50.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.